含整合酶抑制剂抗HIV单片复方制剂与中国HIV感染者常见合并用药的相互作用及临床管理  

Management of drug-drug interactions between INSTI-based single-tablet regimens and common co-medications in people living with HIV in China

作　　者：张仁芳[1] 卢洪洲[1] ZHANG Renfang;LU Hongzhou(Shanghai Public Health Clinical Center,Shanghai 201508,China)

机构地区：[1]上海市(复旦大学附属)公共卫生临床中心,上海201508

出　　处：《中国艾滋病性病》2021年第9期1036-1039,共4页Chinese Journal of Aids & STD

基　　金：国家“十三五”传染病科技重大专项(2017ZX10202101002);重大新药创制专项(2017ZX09304027)。

摘　　要：HIV感染者一方面因免疫功能低下,常患各种机会性感染及肿瘤,另一方面随着寿命延长、人群老龄化,慢性非感染性疾病的发病风险也随之增高,因此常需联合使用其他药物治疗。抗反转录病毒药物与合并用药间的药物-药物相互作用(DDIs)是临床管理的重点之一。随着基于整合酶抑制剂的单片复方制剂(STRs)逐渐成为主流用药趋势,医师需及时更新对这些STRs与常见合并用药间相互作用的认识。本文将主要集中于我国现有的三种STRs,包括艾考恩丙替片、比克恩丙诺片和多替阿巴拉米片,对其各个成分DDI的发生机制以及其与常见感染性、非感染性及非处方合并用药间的DDIs进行总结探讨,以期为临床医师提供参考,合理管理HIV感染者合并用药。People living with HIV(PLWH) are often vulnerable to infectious comorbidities and malignant tumors due to compromised immune systems.The longer life expectancy of PLWH also increases the risk of non-communicable comorbidities,leading to complicated polypharmacy.Therefore,the management of drug-drug interactions(DDIs)between antiretrovirals and co-medications has always been a critical point in the clinical management of PLWH.Recently,integrase strand transfer inhibitor(INSTI)-based single-tablet regimens(STRs) have become a significant preference in HIV treatment.It is thus essential for clinicians to update their knowledge on the DDIs between new STRs and common co-medications.To help clinicians better manage polypharmacy,this article focuses on three newly available STRs in China,namely,E/C/F/TAF,B/F/TAF,and DTG/ABC/3 TC.It also summarises the DDI mechanism of their components and reviews the potential DDIs between these STRs and common co-medications used by PLWH.

关 键 词：艾滋病病毒 整合酶抑制剂 单片复方制剂 药物间相互作用 

分 类 号：R512.91[医药卫生—内科学] R373.9[医药卫生—临床医学]